In the absence of adverse features, regular narrow-complex tachyarrhythmia can be treated with:
vagal manouevres or adenosine In the absence of adverse features you should start with vagal manoeuvres: Carotid sinus massage or the Valsalva manoeuvre will terminate up to a quarter of episodes of paroxysmal SVT. An ECG (preferably multi-lead) should be recorded during each manoeuvre. If the rhythm is atrial flutter with 2:1 conduction, slowing of the ventricular response will often occur and reveal flutter waves, if this is the case seek expert help. If vagal manoeuvres do not terminate the arrhythmia or demonstrate underlying atrial flutter consider using adenosine. If vagal manoeuvres have been attempted and the arrhythmia persists (and it is not atrial flutter) give adenosine 6 mg IV as a very rapid bolus. Use a large cannula and a large (e.g. antecubital) vein. Remember to: check for contraindications such as asthma warn the patient that they will feel unwell and experience chest discomfort for a few seconds after the injection record the ECG continuously (preferably multi-lead) during the injection. If the ventricular rate slows transiently, but then speeds up again, look for atrial activity such as atrial flutter (or other atrial tachycardia) and treat accordingly. If there is no response to adenosine 6 mg, give a 12 mg bolus. If there is again no response give one further 12 mg bolus. Lack of response to adenosine will occur if the bolus is given too slowly or into a small peripheral vein.
Hyperkalaemia in cardiac arrest treatement
What is this?

Mobitz Type II AV block
There is a constant PR interval in the conducted beats but some of the P waves are not conducted (i.e. followed by QRS complexes), in this case producing 2:1 AV block. This may occur randomly, without any consistent pattern. People with Mobitz II AV block have an increased risk of progression to complete AV block and asystole.
2:1 AV block describes the situation in which only alternate P waves are followed by a QRS complex. 2:1 AV block may be due to Mobitz I or Mobitz II AV block and it may be difficult to distinguish which it is from the ECG appearance. If bundle branch block is present (broad QRS complexes) as well as 2:1 block, this is likely to be Mobitz II block.
If tachyarrythmia shows adverse features….
Synchronised DC shock (up to 3 attempts) If this does not work give… Amioderone 300mg IV (10-20 mins) Repeat shock Then give amioderone 900mg over 24 hours
Treatment of acute astma
IF LIFE-THREATENING FEATURES ARE PRESENT:
Acute severe asthma
Features of acute severe asthma:
Peak expiratory flow (PEF) 33–50% of best (use % predicted if recent best unknown).
Can’t complete sentences in one breath.
Respiration >25breaths/minute.
Pulse >110beats/minute.
normocarbia
(PaCO2 4.7-6.0 kPa)
Life threating asthma
Any one of the following, in a patient with severe asthma:
In these patients following senior advise would give amiopylinne. Loading dose is 5mg Kg IV over 20 mins unless already on on maintanace)
Unstable angina and NSTEMI treatment
Adverse features
The following adverse features indicate that a patient is at risk of deterioration either wholly or partly because of their arrhythmia: Shock - features include: hypotension (systolic blood pressure <90 mmHg), pallor, sweating, cold extremities, confusion and impaired consciousness Syncope - transient loss of consciousness because of global reduction in blood flow to the brain Heart failure - features include: pulmonary oedema and/or raised jugular venous pressure (with or without peripheral oedema and liver enlargement) Myocardial ischaemia -features include: typical ischaemic chest pain and/or evidence of myocardial ischaemia on a 12-lead ECG
In patients with adverse features of a bradycardia?
Give Atropine 500 mcg IV.
If there is not a satisfactory response, this dose of atropine may be repeated (every 3-5 mins) up to a maximum total doses of 3 mg.
If atropine fails to provide a satisfactory response you should consider transcutaneous pacing. If this is not available immediately options for treatment using other drugs are listed in the algorithm.
Absolute contraindications to fibrinolytic therapy
What is this?

Agonal rhythm occurs in dying patients.
It is characterised by the presence of slow, irregular, wide ventricular complexes, often of varying morphology. These are unlikely to produce a pulse.
Which of the following drugs may be used for the treatment of sinus tachycardia?
Sinus tachycardia is not an arrhythmia. It is a common physiological response to stimuli such as exercise or anxiety. Do not attempt to treat sinus tachycardia with cardioversion or anti-arrhythmic drugs as treatment is directed at the underlying cause.
When bradycardia is so profound that it causes clinical cardiac arrest
percussion pacing may be used in preference to CPR because it may produce an adequate cardiac output with less trauma to the patient.
To perform percussion pacing:
If attempted percussion pacing does not achieve a cardiac output within a few seconds, start CPR.
STEMI - further management
Anti-thrombotic therapy Beta blocker - (if no asthma - reduces risk of death) ACE inhibitor - (improves likely hood of developing LV failure) Coronary angiography and reperfusion strategies
What is this?

Mobitz Type I AV block (also called Wenckebach AV block)
The PR interval shows progressive prolongation after each successive P wave until a P wave occurs without a resulting QRS complex. Often the cycle is then repeated.
The need for treatment is dictated by the effect of the arrhythmia on the patient and the risk of developing more severe AV block or asystole.
Anaphylaxsis treatment
500micrograms IM adrenaline (1:1000),
oxygen, fluids and bronchodilators.
Antihistamines and hydrocortisone are second line drugs.
Chloraphenamine 10mg IM / slow IV
Hydrocortisone 200mg IM / slow IV
In a stable patient with a broad-complex tachycardia which one of the following would be the recommended first-line treatment?
The appropriate choice is amiodarone 300 mg intravenously over 20-60 min. A 900 mg infusion of amiodarone over 24 h may be used after the initial 300 mg dose
Patients with bradicardia who are at risk of asystole
recent asytole
mobitz II AV block
Complete Heart Block with broad QRS
Ventricular pause > 3 s
Commonest cause of cardiac arrest and sudden cardiac death in adults
Coronary artery disease Other causes include structural heart disease and ‘electrical’ abnormalities
What is this?

First-degree atrioventricular (AV) block is present when the PR interval is > 0.20 s and is a common finding. It represents a delay in conduction through the AV junction (the AV node and immediately adjacent myocardium).
First-degree AV block rarely causes any symptoms and as an isolated finding rarely requires treatment.
The normal PR interval is 0.12-0.20 s (or 3-5 small squares).
In AF can treat with:
If the aim is to control a patient’s heart rate, the usual drug of choice is a beta blocker. Diltiazem may be used in patients in whom beta blockade is contraindicated (e.g. by asthma) or not tolerated. Digoxin may be used in patients with heart failure. Beta blockers, diltiazem and digoxin should be given orally in the first instance unless the patient has contraindications, is vomiting or is critically unwell. In these circumstances the IV route may be used. If the duration of atrial fibrillation is under 48 hours, and rhythm control is considered the appropriate strategy, chemical cardioversion may be appropriate. Drugs such as flecainide may be used but you should always seek expert help before using it. Do not use flecainide in the presence of heart failure, known left ventricular impairment, ischaemic heart disease, or a prolonged QT interval. Amiodarone (300 mg over 20-60 min followed by 900 mg over 24 h) may be used to attempt chemical cardioversion but is less often effective than drugs like flecainide and takes longer to work. Electrical cardioversion remains an option in this setting and will restore sinus rhythm in more patients than chemical cardioversion.